Raffaele Colombo: TOPO1i ADC after TOPO1i ADC?

Raffaele Colombo shared on X:

“TOPO1i ADC after TOPO1i ADC?

ADC-LOW: a French, multicentric, retrospective study evaluating the efficacy of subsequent use of sacituzumab govitecan (SG) and trastuzamab deruxtecan (T-DXd) in patients with HR+/HR− and HER2-low MBC.”.

Source: Raffaele Colombo/X

Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer

Authors: F. Poumeaud, M. Morisseau, L. Cabel, A. Gonçalves, C. Rivier, O. Trédan, E. Volant, J.-S. Frenel, S. Ladoire, W. Jacot, M. Jamelot, H. Foka Tichoue, A. Patsouris, L. Teixeira, F.-C. Bidard, D. Loirat, M. Brunet, C. Levy, C. Bailleux, B. Cabarrou, A. Deleuze, L. Uwer, E. Deluche, T. Grellety, C. Franchet, F. Fiteni, H. Bischoff, R. Vion, M. Pagliuca, B. Verret, S. Bécourt, T. Reverdy, A. de Nonneville and, F. Dalenc 

Raffaele Colombo, a  leading figure in the pharmaceutical industry is the Associate Director of Medicinal Chemistry at Zymeworks Inc.. His leadership and scientific acumen drive the discovery and optimization of novel drug candidates and advancing the treatment landscape for various diseases.